Dave L Dixon Selected Research

4-nitro-3-dimethylaminopropiophenone

9/2022	Survey of CDC-recognized community pharmacies providing the National Diabetes Prevention Program and impact of the COVID-19 pandemic on program delivery.
4/2021	An ounce of prevention is worth a pound of cure: considerations for pharmacists delivering the National Diabetes Prevention Program.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Dave L Dixon Research Topics

Disease

14	Cardiovascular Diseases (Cardiovascular Disease) 10/2022 - 01/2017
12	Heart Failure 01/2022 - 06/2016
7	Type 2 Diabetes Mellitus (MODY) 09/2022 - 01/2018
6	Dyslipidemias (Dyslipidemia) 12/2021 - 01/2018
5	Atrial Fibrillation 10/2022 - 06/2009
5	Myocardial Infarction 12/2021 - 10/2015
4	COVID-19 09/2022 - 01/2021
4	Hypertension (High Blood Pressure) 01/2022 - 04/2014
3	Hemorrhage 12/2021 - 01/2020
3	Weight Loss (Weight Reduction) 01/2020 - 01/2018
3	Injection Site Reaction 01/2020 - 01/2019
3	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 07/2019 - 09/2014
2	Inflammation (Inflammations) 01/2022 - 09/2017
2	Stroke (Strokes) 12/2021 - 01/2019
2	Chronic Renal Insufficiency 01/2021 - 01/2018
2	Obesity 08/2019 - 11/2018
2	Body Weight (Weight, Body) 01/2019 - 01/2018
2	Coronary Disease (Coronary Heart Disease) 01/2018 - 09/2014
2	Hyperlipidemias (Hyperlipidemia) 01/2017 - 02/2015
1	Pericarditis 10/2022
1	Gastrointestinal Diseases (Functional Gastrointestinal Disorders) 12/2021
1	Prediabetic State (Prediabetes) 04/2021
1	Critical Illness (Critically Ill) 01/2021
1	Edema (Dropsy) 01/2021
1	Hyperkalemia 01/2021
1	Drug-Related Side Effects and Adverse Reactions 01/2020
1	Death (Near-Death Experience) 01/2020
1	Unstable Angina 01/2020
1	Infections 01/2020
1	ST Elevation Myocardial Infarction 01/2020
1	Acute Coronary Syndrome 01/2020
1	Peripheral Arterial Disease 07/2019
1	Hypercholesterolemia 07/2019
1	Albuminuria 01/2019
1	Skeletal Abnormalities Mandibular Hypoplasia Auditory Canal Atresia Short Stature 01/2018
1	Chronic Disease (Chronic Diseases) 10/2017

Drug/Important Bio-Agent (IBA)

10	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 10/2021 - 01/2017
7	LipidsIBA 12/2021 - 09/2014
6	oxidized low density lipoproteinIBA 12/2021 - 09/2014
4	Interleukin-1 (Interleukin 1)IBA 01/2022 - 06/2016
4	Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA 12/2021 - 01/2021
4	Triglycerides (Triacylglycerol)IBA 10/2021 - 07/2017
4	LDL CholesterolIBA 05/2021 - 09/2014
4	Glucose (Dextrose)FDA LinkGeneric 01/2019 - 01/2018
3	C-Reactive ProteinIBA 01/2022 - 01/2016
3	Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link 01/2022 - 09/2017
3	evolocumabIBA 12/2021 - 01/2017
3	Pharmaceutical PreparationsIBA 01/2021 - 02/2015
3	CanagliflozinIBA 01/2021 - 01/2019
3	SodiumIBA 01/2021 - 01/2018
2	4-nitro-3-dimethylaminopropiophenoneIBA 09/2022 - 04/2021
2	Monoclonal AntibodiesIBA 12/2021 - 01/2020
2	Proprotein Convertase 9IBA 12/2021 - 01/2020
2	alirocumabIBA 12/2021 - 01/2020
2	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 12/2021 - 08/2019
2	Fibric Acids (Fibrates)IBA 10/2021 - 05/2021
2	Niacin (Nicotinic Acid)FDA LinkGeneric 10/2021 - 05/2021
2	HDL CholesterolIBA 10/2021 - 05/2021
2	dalcetrapibIBA 10/2021 - 05/2021
2	Sitagliptin Phosphate (Januvia)FDA Link 01/2021 - 11/2020
2	PotassiumIBA 01/2021 - 10/2015
2	CholesterolIBA 02/2020 - 03/2018
2	Glucagon-Like Peptide-1 Receptor AgonistsIBA 01/2020 - 10/2019
2	Vitamin K FDA Link 01/2020 - 01/2015
2	Glucagon-Like Peptide 1 (GLP 1)IBA 01/2020 - 10/2019
2	Hypoglycemic Agents (Hypoglycemics)IBA 10/2019 - 05/2017
2	SymportersIBA 01/2019 - 01/2018
2	Sodium-Glucose Transporter 2 InhibitorsIBA 01/2019 - 05/2017
2	Warfarin (Coumadin)FDA LinkGeneric 01/2015 - 06/2009
1	Colchicine FDA LinkGeneric 10/2022
1	Antihypertensive Agents (Antihypertensives)IBA 01/2022
1	Docosahexaenoic AcidsIBA 12/2021
1	AntibodiesIBA 12/2021
1	Eicosapentaenoic AcidIBA 12/2021
1	Immunomodulating AgentsIBA 01/2021
1	sodium zirconium cyclosilicateIBA 01/2021
1	patiromerIBA 01/2021
1	Carbon DioxideIBA 11/2020
1	Hemoglobins (Hemoglobin)IBA 01/2020
1	AnticoagulantsIBA 01/2020
1	sacubitril and valsartan sodium hydrate drug combinationIBA 01/2020
1	semaglutideIBA 01/2020
1	insulin receptor-related receptor (IRR)IBA 01/2020
1	eicosapentaenoic acid ethyl esterIBA 01/2020
1	paragonIBA 01/2020
1	Dipeptidyl-Peptidase IV InhibitorsIBA 10/2019
1	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 10/2019
1	Blood Glucose (Blood Sugar)IBA 01/2019
1	PCSK9 InhibitorsIBA 01/2019
1	AntioxidantsIBA 01/2018
1	Adenosine Triphosphate (ATP)IBA 01/2018
1	empagliflozinIBA 01/2018
1	coenzyme Q10 (CoQ10)IBA 01/2018

Therapy/Procedure

10	Therapeutics 01/2022 - 04/2014
4	Secondary Prevention 10/2022 - 01/2015
3	Drug Therapy (Chemotherapy) 12/2021 - 07/2017
3	Glycemic Control 10/2019 - 05/2017
1	Polypharmacy 01/2020
1	Inappropriate Prescribing 01/2020
1	Surgical Amputation (Amputations) 01/2019